Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
| The Manila Times
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration